BrightPath Biotherapeutics Co (TSE:4594) ROCE % : -166.79% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is BrightPath Biotherapeutics Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BrightPath Biotherapeutics Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -166.79%.

BrightPath Biotherapeutics Co ROCE % Historical Data

The historical data trend for BrightPath Biotherapeutics Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrightPath Biotherapeutics Co ROCE % Chart

BrightPath Biotherapeutics Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-27.39

-43.21

-49.81

-47.95

-70.46

BrightPath Biotherapeutics Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-83.76	-60.47	-79.44	-85.65	-166.79

BrightPath Biotherapeutics Co ROCE % Calculation

BrightPath Biotherapeutics Co's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-1483.672	/	( ( (2771.202 - 184.655)	+	(1701.444 - 76.558) )	/ 2 )
	=	-1483.672	/	( (2586.547	+	1624.886)	/ 2 )
	=	-1483.672	/	2105.7165
	=	-70.46 %

BrightPath Biotherapeutics Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1586.412	/	( ( (1163.667 - 91.997)	+	(1428.572 - 597.902) )	/ 2 )
	=	-1586.412	/	( ( 1071.67	+	830.67 )	/ 2 )
	=	-1586.412	/	951.17
	=	-166.79 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

BrightPath Biotherapeutics Co (TSE:4594) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BrightPath Biotherapeutics Co ROCE % Related Terms

Thank you for viewing the detailed overview of BrightPath Biotherapeutics Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BrightPath Biotherapeutics Co (TSE:4594) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BrightPath Biotherapeutics Co Ltd (TSE:4594) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN

Website

https://www.brightpathbio.com

BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

BrightPath Biotherapeutics Co (TSE:4594) Headlines

No Headlines